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Abstract 38 
 39 
Introduction and objective: Dengue virus is a serious global health problem with an 40 
estimated 3.97 billion people at risk for infection worldwide. In December 2015, the 41 
first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by 42 
Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public 43 
KHDOWKV\VWHPLQIRUPDWLRQLVQHHGUHJDUGLQJFRQVXPHUV¶ZLOOLQJQHVVWRSD\IRUWKH44 
dengue vaccine in the country as well as discussions related to the possible inclusion of 45 
this vaccine into the public health system. This was the objective of this research. 46 
Methods: We conducted a cross-sectional study with residents of Greater Belo 47 
Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. 48 
2 
Results: 507 individuals were interviewed. These were mostly female (62.4%) had 1 
completed high school (62.17%), were working (74.4%), had private health insurance 2 
(64.5%) and did not have dengue (67.4%). The maximum median value of consumerV¶ 3 
willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete 4 
schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's 5 
regulatory chamber of pharmaceutical products market (CMED) for the 6 
commercialization of Dengvaxia® for three doses, only 17% of the population expressed 7 
willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest 8 
markets for dengue vaccine and the price established is a key issue. We believe the 9 
manufacturer should asses the possibility of lower prices to reach a larger audience 10 
among the Brazilian population. 11 
 12 
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 14 
1. Introduction 15 
 16 
Dengue is an arbovirosis transmitted to humans by the bite of a mosquito of the Aedes 17 
genus, especially, Aedes aegypti. It is estimated that 390 million infections occur 18 
annually worldwide (Gubler, 2011; Bhatt et al., 2013), with the number of cases of 19 
dengue increasing in frequency and geographic region (Guzman et al., 2010; Brady et 20 
al, 2012; Simmons et al., 2012; Bhatt et al., 2013). Based on mathematical modelling, 21 
the global annual incidence has been estimated at approximately 50 to 100 million 22 
symptomatic cases each year in recent years (Beatty et al., 2011; Bhatt et al., 2013). 23 
This flavivirus represents an important social and economic impact in most tropical and 24 
subtropical countries, and it is currently estimated that approximately US$5million are 25 
spent annually on hospitalizations related to dengue worldwide (Suaya et al., 2009). 26 
However, this is now likely to be a considerable under-estimate. 27 
 28 
Dengue is endemic in Brazil, with a high and increasing incidence in recent years 29 
(Brasil, 2011; Brasil, 2013; Brasil, 2016). In 2015, there were 1,587,080 registered 30 
cases probably due to dengue, 839 deaths and an incidence of 782.6 cases /100,000 31 
inhabitants. In the State of Minas Gerais, there was a demonstrated incidence of 879.8 32 
cases/100,000 inhabitants and 67 deaths (Brasil, 2016). Data released by the National 33 
Information System of Notifiable Diseases (SINAN) demonstrated the occurrence of 34 
2,320,956 and 4,406,767 cases of dengue in the state of Minas Gerais and Brazil 35 
respectively between 2010 to 2014 (Brasil, 2014a). In 2014, more than 150 million 36 
Brazilian reais (US$42.016million) were spent on surveillance, prevention and control 37 
of dengue and chikungunya virus in Brazil (Brasil, 2014b).  38 
 39 
Until now, there has not been a specific licensed treatment for dengue, and the 40 
development of effective vaccines against all four serotypes of DENV is an important 41 
strategy to control this flavivirus and significantly contribute to reducing the disease 42 
burden (Webster et al., 2009; Durbin et al., 2011). Common strategies to help control 43 
dengue include preventing mosquitoes from accessing egg-larving habitats, using 44 
environmental management interventions such as removing artificial man-made 45 
mosquito habitats, emptying and cleaning domestic water storage containers, as well as 46 
personal and household protection including applying insecticides (WHO, 2016).   47 
 48 
3 
Recently, the tetravalent chimeric vaccine CYD-TDV from Sanofi Pasteur was 1 
approved for the prevention of dengue in endemic countries including Mexico, the 2 
Philippines, El Salvador, Costa Rica, Paraguay and Brazil (Brasil, 2015; DVI, 2015; 3 
Roland et al., 2015). The disappointing results in individuals under 9 years of age 4 
(Hadinegoro et al., 2015) led to vaccine being indicated for the population 9 years or 5 
older. The resultant approved indication from this first dengue vaccine is for individuals 6 
9 to 45 years (e.g. Brazil) or 9 to 60 years of age (e.g. Paraguay), depending on the 7 
license (WHO, 2016).  8 
 9 
CYD-TDV was evaluated during the active phase of surveillance (25 months post-10 
enrolment) in CYD14 (Capeding et al., 2014) and CYD15 (Villar et al., 2015). As per 11 
the protocol, vaccine efficacy against virologically-confirmed symptomatic dengue 12 
illness was 56.5% (95% CI; 43.8% - 66.4%) in CYD14, assessed in Asia, and CYD15 13 
with 60.8% (95% CI; 52% - 68%) evaluated in clinical trials conducted in Latin 14 
America including Brazil. Sanofi Pasteur recommended the administration of three 15 
doses each six months apart (WHO, 2016). However, the complete duration of vaccine 16 
protection is still unknown (HADINEGORO et al., 2015; WHO, 2016).      17 
 18 
The Brazil's regulatory chamber of the pharmaceutical products market (CMED)  is 19 
responsible for evaluating and establishing the prices of medicines for 20 
commercialization in Brazil by Resolution n°2 of 5 March 2004, referencing prices for 21 
the same medicines in other countries including Australia, Canada and the United States 22 
(Brasil, 2004). From prices established by CMED, pharmaceutical companies may 23 
apply for incorporation of their products into the national health system by sending a 24 
process submission to the National Commission on Technology Incorporation of the 25 
National Health System (CONITEC) (Brasil, 2008). In this context, endemic countries, 26 
including e Brazil, will have to make important decisions such as the possible 27 
incorporation of this vaccine into their public systems within a context of constrained 28 
budgets. In this scenario, pharmacoeconomic evaluations, such as the assessment of 29 
willingness-to-pay and cost-effectiveness analysis, are important for decision-making 30 
(Palanca-Tam, 2008; Lee et al., 2015). 31 
 32 
Willingness-to-pay (WTP) is a relevant methodological approach to estimate the 33 
maximum amount that an individual is willing to allocate to programs, services and 34 
health technologies. It is usually applied in cost-benefit analysis and in health 35 
technology assessment (Haab and Mcconnell, 2002). The lack of available WTP studies 36 
with the Brazilian consumer for a dengue vaccine, and the possible upcoming 37 
vaccination with CYD-TDV in the country, is a concern given the potential budget 38 
impact and the current economy situation. This study sought to estimate the Brazilian 39 
consumerV¶ willingness to pay for this vaccine in order to contribute to the debate and 40 
pharmacoeconomic reviews focusing on demand  and potential prices for dengue 41 
treatments in Brazil. 42 
 43 
2. Material and Methods 44 
 45 
This study estimated the willingness to pay of Brazilian consumers towards the CYD-46 
TDV dengue vaccine through an analysis of contingent valuation, which enables 47 
evaluation of the monetary amount an individual is willing to pay to acquire a certain 48 
4 
product or service using questionnaires with direct questions. The respondents did not 1 
have the disease at the time of the interview, but they may or may not have had dengue 2 
in the past (Haab and Mcconnell, 2002).  3 
 4 
2.1 Design and study location 5 
The survey was conducted in the metropolitan region of Belo Horizonte, capital of 6 
Minas Gerais State, the second most populous state in Brazil. Minas Gerais state has 7 
21,013,869 inhabitants with 2,375,151 inhabitants currently registered in the Belo 8 
Horizonte metropolitan region. In addition, Belo Horizonte and Brazil presented, 9 
respectively, a mean Human Developed Index of 0.810 and 0.737 in 2010 (Atlas do 10 
Desenvolvimento Humano, 2016).  11 
 12 
Minas Gerais State is similar to Brazil as a whole for certain aspects including mean 13 
income per capita and socio demographics. Mean income per capita  was US$315.97 14 
(1128.00BRL) for Brazil and US$311.76 (1113.00BRL) per month for Minas Gerais in 15 
2015 (IBGE, 2014; Agencia Brasil, 2016). In addition, despite that there being 26 States 16 
in the country, Minas Gerais has one sixth of the Brazilian cities and represents a 17 
relevant epidemiological context for the flavivirus (BRASIL, 2014a; 2016). In addition 18 
n 2013, Minas Gerais was the State with the highest number of dengue cases in the 19 
country (Brasil, 2014a). Consequently, providing a robust sample for the study. 20 
 21 
Participants were interviewed using a questionnaire developed by the research team, 22 
based on a literature review (Haab and Mcconnell, 2002; Palanca-Tam, 2008; Lee et al., 23 
2015). The survey was conducted in May 2016 and the interviewers were undertaken by 24 
graduate and undergraduate students of the Faculty of Pharmacy of the Federal 25 
University of Minas Gerais, trained to conduct interviews and answer possible 26 
questions. 27 
 28 
2.2 Data collection instrument 29 
The technique for measuring the willingness to pay is the application of a questionnaire, 30 
with prior presentation to the respondent of all the features of the disease and the 31 
intervention necessary for decision-making, as well as the involved conditions and 32 
important aspects of the clinical context of the disease. To fully implement this 33 
technique, it is essential that all participants have received the same information. This 34 
was assured by specific and intensive training of the interviewers (Haab and Mcconnell, 35 
2002).  36 
 37 
The questionnaire was divided in five sections: (1) Questions to understand what the 38 
participants knew about dengue; (2) Information about the disease, intervention and 39 
alternatives for disease prevention; (3) Questions to test the understanding of the 40 
information provided; and (4) Discrete Choice, Bidding Game and Open-Ended 41 
questions (Haab and Mcconnell, 2002).  Section 5 consisted of a self-reported 42 
socioeconomic questionnaire. The questions in section (4) were included in order to 43 
assess whether individuals would be willing to pay US$54.05 (180.00 BRL) for the 44 
three-dose scheme of CYD-TDV vaccine as well as obtain an estimate of a range of 45 
values and a point estimate that respondents would pay for the technology.  46 
 47 
5 
US$54.05 for three doses of CYD-TDV for the Discrete Choice technique was 1 
established based on the maximum price for the consumer of the yellow fever vaccine - 2 
US$19.50 (64.92BRL) (Fiocruz Laboratory), established by CMED in 20 July 2016 3 
(Anvisa, 2016). 4 
 5 
All questions related to the research context and/or difficulties in completing the 6 
socioeconomic questionnaire were clarified by the interviewers. The information about 7 
the mean effective protection for all four serotypes (approximately 60%), as well as the 8 
possibility of local (e.g. swelling at the site of application and pain) and systemic (e.g. 9 
fever, myalgia, asthenia and headache) adverse events were included in the text read to 10 
all participants in the initial stage of the interview. There was also a figure explaining 11 
graphically the efficacy of the vaccine to aid the dissemination of information. 12 
 13 
2.3 Sampling and selection criteria 14 
Interview selection was random. Passers by in major circulation paths, close to parks, 15 
markets and fairs in the metropolitan region of Belo Horizonte were invited to 16 
participate and, if they agreed, answered the questionnaire in the same location. 17 
Considering the scenario with higher uncertainty that is 50% respondents agreeing to 18 
pay the value of US$54.05 (180.00BRL), with a two-sided 0.05 significance, we 19 
calculated a minimum of 400 respondents would be required in this research. .  20 
 21 
Individuals could or not have history of dengue, but could not presently have symptoms 22 
or have a diagnosis of the disease at the time of the interview. To be selected, 23 
individuals must have declared that they have an income. Individuals under 18 without 24 
their own income were excluded. In addition, participants who showed willingness to 25 
pay higher than twice the value of their declared monthly income and individuals who 26 
would not use this vaccine, even if it would be free, were excluded from the analysis in 27 
line with previous publications  (Lee et al., 2015). 28 
 29 
2.4 Data analysis 30 
The willingness to pay for dengue vaccine was estimated by the median of the 31 
maximum declared value by the individuals who were willing to pay any amount 32 
greater than or equal to zero. The median among groups defined by covariates were 33 
compared using the Mann-Whitney test (two groups) or Kruskal-Wallis test (three or 34 
more groups). The significance level was 5%. All socioeconomic variables were 35 
evaluated and the relation with the maximum value of willingness to pay for CYD-36 
TDV, such as education and income were included. To assess income variation, we 37 
stratified the value of "<3"; "3-10" and "> 10" times the minimum wage, in order to 38 
measure the percentage of individuals for each range.  39 
 40 
Furthermore, we measured the frequency of the participants that have or not private 41 
health insurance. According to the National Regulatory Agency for Private Health 42 
Insurance and Plans (ANS), that regulates the private health insurances in Brazil, Minas 43 
Gerais has a coverage of private health insurance of between 20% and 30%, with 44 
5,467,559 beneficiaries in the State in 2014. The coverage in Brazil was 25.2% of the 45 
population (48,824,150 individuals) in March 2016 (ANS, 2016a; b). 46 
  47 
6 
In addition, we further evaluated the relation of willingness to pay by individuals that 1 
had previously had or not dengue. Statistical analysis was performed using Microsoft 2 
Excel 2007, R (R CORE TEAM, 2014) and Minitab 17. For comparison purposes, we 3 
adopted the conversion value established by the World Bank for Purchasing Power 4 
Parities (PPPs) (2015: 1 US$ = 3.330BRL).  5 
 6 
2.5 Ethical considerations 7 
All interviews were conducted after reading and signing the Term of Free and Clarified 8 
Consent. All researchers of the project signed a confidentiality agreement prior to the 9 
interviews. This study was approved by the Ethics Committee of the Federal University 10 
of Minas Gerais (COEP) under the CAAE 57219816.0.0000.5149. 11 
 12 
3. Results 13 
 14 
3.1 Population characteristics 15 
We conducted 507 interviews with individuals aged between 18 and 84 years old who 16 
agreed to participate and answer the questionnaire. The mean age of respondents was 17 
34.6±12.8 years, 37.6% were male, 74.4% were working at the time of interview, and 18 
37.8% had completed higher education (Table 1).  19 
 20 
The participants who reported a history of dengue were 32.6%, the utilization of public 21 
health service was reported by 49.3%, and those respondents who reported at least one 22 
dengue case in the household were 43.8%. In approximately 70% of respondents, their 23 
family income was below five times the minimum wage (Table 1).  24 
7 
Table 1. Characteristics of the respondents 1 
 2 
Variable n  (%)** 
Age in years [mean (SD)] 34.6  12.5% 
Men  188  37.6% 
Has children 197  (38.9%) 
Educational level   
Had never attended school 2  0.4% 
Complete primary education 46  9.3% 
Completed high school 261  52.5% 
Complete college or more 188  37.8% 
   
Currently working 372  74.4% 
Have health insurance 318  64.5% 
   
Dengue history  162 32.6% 
Had dengue and reported having used only the public health 
system 
68  
49.3% 
Had dengue and reported having used only a private health 
provider 
54  
39.1% 
Had dengue and reported have used both services 16  11.6% 
Reported that other people in the household had dengue 212  43.8% 
Family income (number of minimal wages)*   
<1  8.5% 
1-2  15.4% 
2-3  15.2% 
3-5  20.7% 
5-10  22.5% 
10-20  7.9% 
>20  1.2% 
Notes: * 8.6% of respondents refused to answer on family income. **The value of the difference to reach 3 
LQDOOTXHVWLRQVDUHGXHWRDQVZHUVVXFKDV³,GRQRWNQRZ´DQG³,GRQRWZDQWWRDQVZHU´ 4 
 5 
3.2 Willingness to pay for CYD-TDV dengue vaccine 6 
Of the 507 subjects, 7.3% said they would not be vaccinated even if CYD-TDV did not 7 
have any cost. The main reasons for this were efficacy (37.8%) and safety (40.5%). In 8 
addition, only three (8.1%) respondents said they did not use any vaccines and fifty-nine 9 
(11.6%) said they would use this vaccine only if it would be provided free of charge. 10 
Considering these exclusions criteria, 464 respondents were eligible for the WTP 11 
analysis.  12 
 13 
Among these 464 individuals, 37.9% were men, 88.8% had completed high school or 14 
more, 39.2% had children, 73.7% were working at the moment of interview, 62.1% had 15 
health insurance and 31.7% had previously had dengue. The participants who reported a 16 
family income up to 10 times the minimal wage were 83.4% (Figure 1). 17 
 18 
8 
Figure 1. Family income of respondents included in analysis of the willingness to pay 1 
for dengue vaccine (Dengvaxia®) in this study 2 
 3 
       * NA: Not available - 7KHUHVSRQGHQWVWKDWDQVZHUHG³,GRQRWNQRZDQG,GRQRWZDQWWRDQVZHU´; 4 
mw = minimal wage  5 
With the application of the Discrete Choice Technique, it was found that 44% of 6 
participants were willing to pay US$54.05 (180.00BRL) for the three-dose regimen of 7 
the vaccine. Of the 190 respondents who had children, 131 (68.9%) were willing to pay 8 
USD$54.05 for CYD-TDV vaccination of their family. Results of the Bidding Game 9 
technique revealed that, in general, the amount the respondents were willing to pay 10 
ranged from US$27.03 (90.00BRL) to US$108.11 (360.00BRL), representing 54.1% of 11 
individuals involved in interview. The minimum and maximum willingness to pay for 12 
three doses of CYD-TDV vaccine were of 0.00 and 1,800.00 BRL. 13 
 14 
The willingness to pay for dengue vaccine by the Brazilian consumer was estimated at 15 
the median value of US$36.04 (120.00BRL) for the three-dose regimen or US$12.01 16 
(40.00BRL) per dose. This means that 50% of individuals interviewed reported 17 
maximum values of willingness to pay equal to or less than US$36.04 (Figure 2).  18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
9 
Figure 2. Cumulative percentage of individuals willing to pay for CYD-TDV vaccine 1 
according to the maximum values reported 2 
 3 
The only variable correlated with willingness to pay with statistical significance (<0.05) 4 
was monthly income (p = 0.003) when stratified as "<3", "3-10" and "> 10" times the 5 
minimum wage, representing family income values under US$739.50 (2,640.00BRL) 6 
(30.8%), between US$792.79 (2,640.00BRL) and US$2,642.64 (8,800.00BRL) (34.1%) 7 
and above US$2,642.64 (6.9%), respectively, per month. Median values of willingness 8 
to pay for these three groups were respectively US$30.03 (100.00BRL) and US$54.05 9 
(180.00BRL) for the highest income groups (Figure 3). As expected, the increase of 10 
family income contributed to a higher willingness to pay, which is logical and 11 
consistent with the published theory (Haab and Mcconnell, 2002). 12 
 13 
10 
Figure 3.  Box plot of the willingness to pay for three doses of CYD-TDV according to 1 
family income. 2 
 3 
NB. The results were statistically significant (< 0.05); (*) Extreme values presented for each income 4 
range; mw = minimal wage 5 
 6 
 7 
Discussion 8 
 9 
This study sought to estimate the willingness to pay among Brazilian consumers for the 10 
dengue vaccine recently licensed in the country, with the study population having 11 
similarities with the profile of the Brazilian population as a whole. This included certain 12 
characteristics such as higher percentage of women (51.4%), a low percentage of 13 
individuals who have never studied (8.5%) and the percentage of individuals with at 14 
least 11 years of education (41.8%) (IBGE, 2014). The percentage of families in our 15 
study with income less than 5 times the minimum wage was just under 70% (Table 1). 16 
This value was below the Brazilian Institute of Geography and Statistics (IBGE) in their 17 
profiling family in the national context, where the percentage was 87.9%. This might 18 
contribute for a higher median value of willingness to pay for the vaccine compared to 19 
the national population (IBGE, 2014). 20 
 21 
In this study, the percentage of respondents who reported having health insurance was 22 
64.5% (ANS, 2016b). The Brazilian private market for health insurance is strictly 23 
regulated by the National Regulatory Agency for Private Health Insurance and Plans, 24 
which works on behalf of the Ministry of Health. Private health insurance can either be 25 
purchased individually or obtained as a work benefit, depending on the employer. The 26 
Brazilians that decide to purchase private health insurance may still access public health 27 
services if they wish or need. The Brazilian public health system, named SUS, was 28 
established in 1988 by constitution in order to guarantee access to health care to the 29 
entire population. The public system maintains primary and outpatient centers, 30 
hospitals, diagnostic laboratories and should provide access to pharmaceuticals 31 
including vaccines (Rizzotto and Campos, 2016).  32 
11 
   1 
The median willingness to pay value for CYD-TDV was US$33.61 (120.00/11.20BRL 2 
dose) for the three-dose scheme and clinical efficacy of 60% (Hadinegoro et al., 2015; 3 
Godói et al., 2016). The reason for expressing values in medians in willingness to pay 4 
analysis (Palanca-Tam, 2008; Hadisoemato et al., 2013; Lee et al., 2015) is that the 5 
mean is sensitive to outliers, which may contribute to an erroneous perception of what 6 
the population is indeed willing to pay. The median value of US$33.61 shows the 7 
maximum amount 50% of respondents would be willing to pay; however, this does not 8 
represent an estimated average number of people willing to pay for the vaccine 9 
(Buckland et al., 1999).  10 
 11 
This study is the first study in Brazil to consider the actual scenario of a possible 12 
vaccination with CYD-TDV with clinical information arising from clinical phase III 13 
trials (Capeding et al., 2014; Villar et al., 2015) and from the 25 months follow-up 14 
study (Hadinegoro et al., 2015). Other studies adopted a hypothetical vaccination 15 
scenario with 100% safety and efficacy and with protection for 10 years and for life, as 16 
seen, respectively, in the studies conducted in the Philippines (Palanca-Tam, 2008) and 17 
Indonesia (Hadisoemato et al., 2013). However, we believe this is an unrealistic 18 
scenario given the current clinical information. 19 
 20 
The number of doses used in the studies was also variable. A single dose study was 21 
conducted in the Philippines (PALANCA-TAM, 2008) and Indonesia (Hadisoemato et 22 
al., 2013) and three doses in Vietnam, Thailand and Colombia (Lee et al., 2015), which 23 
is similar to our study. Among the respondents in our study, 7.3% reported not wishing 24 
to be vaccinated even if the vaccine was free of charge. The same situation happened in 25 
the studies from Vietnam, Thailand and Colombia (Lee et al., 2015). 26 
 27 
The willingness to pay of Brazilian consumers of US$33.61 (BRL120.00) is closer to 28 
that observed in endemic countries such as Vietnam and Colombia. This is between the 29 
values found in Vietnam at US$26.13 and the Philippines at US$60.00. The observed 30 
values in Indonesia, Colombia and Thailand and were respectively US$ 1.94, US$22.60 31 
and US$ 69.78. The studies published in the context of willingness to pay for dengue, in 32 
general, considered a hypothetical dengue vaccine with results of efficacy, safety and 33 
protection time better than the results seen with CYD-TDV in phase III clinical trials 34 
(Palanca-Tam, 2008; Hadisoemato et al., 2013; Lee et al., 2015). Consequently, again 35 
questioning the findings. 36 
 37 
The Brazil's regulatory chamber of pharmaceutical products market is an inter-38 
ministerial body responsible for price setting. New-patented innovative products such as 39 
Dengvaxia® are classified as Class I. As a result, manufacturer prices may not exceed 40 
the lowest price in the following markets: Australia, Canada, France, Greece, Italy, New 41 
Zealand, Portugal, Spain or United States of America (Brasil, 2004). However since 42 
CYD-TDV is not marketed in these countries, CMED had no comparison to establish a 43 
price for vaccine in Brazil. On July 25th of 2016, CMED reported that the manufacturer 44 
price for each Dengvaxia® dose in Brazil may vary from US$37.19 to US$38.80 45 
(132.76 to 138.53BRL) according to the States (provinces) tax rates of each of the 26 46 
states of Brazil. For Minas Gerais State, the maximum consumer price is US$37.71 47 
(134.63BRL). Considering the need for three doses of the vaccine to achieve planned 48 
12 
efficacy, the amount paid for each person vaccinated will be at least US$113.13 1 
(403.89BRL), which represents the willingness to pay of only 17% of the population in 2 
this study.  3 
 4 
Mahoney et al (2012) studying the production costs of another dengue vaccine, which is 5 
being developed at the Butantan Institute, found that the production scale (15 million 6 
doses per year) in ten vials should cost around US$0.51 to US$0.65 per vial. When the 7 
quantity produced increases to 60 million doses per year, the cost of production could 8 
potentially fall to US$0.20 per dose. The authors demonstrated that vaccines for 9 
Japanese encephalitis and type A meningitis are available in developing countries at 10 
prices below US$1.00 per dose. This is much lower than consumer prices demanded by 11 
manufacturer in Brazil or established by CMED.   12 
 13 
Brazil has a comprehensive immunization program with coverage for an appreciable 14 
number of infections. In future scenarios, we believe public health systems purchasing 15 
the dengue vaccine should assess carefully the cost-effectiveness ratio in combination 16 
with a budget impact analysis, as the efficacy of this new dengue vaccine may be 17 
considered insufficient compared to other vaccines for similar conditions or disease 18 
burden with appreciably lower prices. Comparisons with other vaccines prices and 19 
effectiveness for diseases with similar burden may contribute to political decisions 20 
regarding the possibility of incorporating this technology into public health systems at 21 
acceptable and reasonable prices, bearing in mind the current economic climate in 22 
Brazil and the desire to continue to offer universal healthcare. Such discussions have 23 
grown in recent times driven by the increasing prices for new medicines especially new 24 
cancer medicines and those for orphan diseases, despite costs of research and 25 
production estimated at US$50 to 100 million per compound by some authors (Experts 26 
in Chronic Myeloid Leukemia, 2013; Godman et al 2015; Howard et al., 2015; Tefferi 27 
et al., 2015; Phelan et al., 2014; Bruijin et al., 2016). 28 
 29 
In a study conducted in Brazil, Araújo et al (2016) estimated the potential impact of 30 
vaccination against dengue. In a more conservative scenario, the authors estimated a 31 
22% reduction in cases of dengue (routinely vaccinate up to 9 years old and vaccination 32 
campaign up to 10 years) and 81% in the liberal scenario (routine to 9 years and 33 
vaccination campaign up to 40 years) over 5 years. Furthermore, they demonstrated that 34 
vaccination could reduce 233,000 hospitalizations due to the disease during the 35 
considered period. CYD-TDV was licensed for individuals with age between 9 and 45 36 
years old (Brasil, 2015a).  However, it is important to balance this against the potential 37 
budget impact. This especially as it is important to emphasize that all efforts and 38 
strategies for vector control by governments and society will need to continue since the 39 
vaccine has only 60% efficacy, and especially because of other existing arboviruses, 40 
such as Chikungunya and Zika, with Zika related to microcephaly epidemics in Brazil 41 
(Brasil, 2015b).  42 
 43 
The contingent valuation is the most common approach to estimate the monetary value 44 
for goods and services from hypothetical questions (Haab and Mcconnell, 2002; 45 
Palanca-Tam, 2008; Hadisoemato et al., 2013; Lee et al., 2015). However, some 46 
limitations are noted such as the respondents may not have full information (e.g. 47 
disease, severity and frequency of symptoms) or that it may simulate a scenario very 48 
13 
distinct and different compared with the real situation (e.g. efficacy of the intervention). 1 
To avoid such limitations, the questionnaire used must be complete and up to date and 2 
include all relevant situations and conditions related to the intervention or service in the 3 
analysis to avoid possible bias (Boyle, 2003). This study was conducted using efficacy 4 
results extracted from the analysis of 27,355 individuals from 2 to 16 years old 5 
(Hadinegoro et al., 2015). These results was used to grant commercial license to 6 
Dengvaxia® for children as well as adults in Brazil and in other countries (Godói et al., 7 
2016). Consequently, helping to address such concerns. Real-world results of the 8 
vaccine are currently missing, which may overestimate the value of the WTP (if 9 
effectiveness is lower), or underestimate the value (if effectiveness is higher ± most 10 
XQOLNHO\VFHQDULR,QDGGLWLRQWKHUHVSRQGHQW¶VZLOOLQJQHVVWRSD\ZHUHFRQVWUDLQHG11 
within the attributes and levels presented in this study. Lastly, the random sample used 12 
may not be fully generalizable to population of Brazil as a whole. However despite 13 
these limitations, we believe our findings do provide guidance to the Brazilian 14 
authorities and the manufacturers of the vaccine on potential pricing and reimbursement 15 
strategies.  16 
 17 
In conclusion, despite the limitations regarding income differences between citizens in 18 
Minas Gerais and Brazil as a whole as well as limitations with the sampling method, we 19 
believe this study provides important information about how much consumers are 20 
willing to pay for the CYD-TDV vaccine approved in Brazil to avoid the risk of being 21 
infected. From the price determined by CMED for commercialization of Dengvaxia® 22 
(Minas Gerais) i.e. US$113.13 for three doses, only 17% of the participants involved in 23 
this study were willing to pay for this vaccine, and this from a higher income base than 24 
Brazil as a whole. This is a concern given the current resource constrained environment 25 
in Brazil. We believe based on our study findings, that the manufacturers may wish to 26 
reconsider their pricing strategy. This is because Brazil constitutes one of the largest 27 
markets for dengue vaccine and there are appreciable competing demands on available 28 
resources, especially given the current economic situation in Brazil.  29 
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